Targeted inhibition of human breast cancer cell line selected as model system of ERBB2-positive breast cancer [RPPA-Longterm-BT474]
收藏NIAID Data Ecosystem2026-03-08 收录
下载链接：
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50107
下载链接
链接失效反馈官方服务：
资源简介：
EGFR-inhibition is required for targeted therapies of ERBB2-positive/EGFR high breast cancer. Approximately 30% of human ERBB2-positive breast tumors also express EGFR. Three therapeutics were analyzed in five combinations plus control. Each experiment was performed in three biological replicates. This resulted in 180 samples. Exceptionally, time point 18 has just two biological replicates, and time point 48 just one. A dilution series of control lysated was included as control.
创建时间：
2014-08-15
